Organon & Co (OGN) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Organon & Co

NYSE | OGN

14.45

USD

-0.27 (-1.83%)

AT CLOSE (AS OF Apr 3, 2025)

$3.8B

MARKET CAP

4.42

P/E Ratio

3.33

EPS

$22

52 Week High

$14

52 Week Low

LIFE SCIENCES

Sector

OGN Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

OGN Technicals

Tags:

OGN Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$1.7B
Total Revenue	$6.3B
Cost Of Revenue	$4.6B
Costof Goods And Services Sold	$2.5B
Operating Income	-$922M
Selling General And Administrative	$1.9B
Research And Development	$528M
Operating Expenses	$2.6B
Investment Income Net	-
Net Interest Income	-$527M
Interest Income	-
Interest Expense	$527M
Non Interest Income	-$42M
Other Non Operating Income	-
Depreciation	$120M
Depreciation And Amortization	$116M
Income Before Tax	$673M
Income Tax Expense	-$350M
Interest And Debt Expense	$527M
Net Income From Continuing Operations	$1B
Comprehensive Income Net Of Tax	$1B
Ebit	$1.2B
Ebitda	$1.3B
Net Income	$1B

Revenue & Profitability

Earnings Performance

OGN Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$12B
Total Current Assets	$4.5B
Cash And Cash Equivalents At Carrying Value	$693M
Cash And Short Term Investments	$693M
Inventory	$1.3B
Current Net Receivables	$1.7B
Total Non Current Assets	$6.6B
Property Plant Equipment	$1.2B
Accumulated Depreciation Amortization Ppe	$1B
Intangible Assets	$5.1B
Intangible Assets Excluding Goodwill	$533M
Goodwill	$4.6B
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$756M
Other Non Current Assets	-
Total Liabilities	$12B
Total Current Liabilities	$2.9B
Current Accounts Payable	$1.3B
Deferred Revenue	-
Current Debt	$9M
Short Term Debt	$9M
Total Non Current Liabilities	$9.4B
Capital Lease Obligations	-
Long Term Debt	$8.8B
Current Long Term Debt	$9M
Long Term Debt Noncurrent	$8.8B
Short Long Term Debt Total	$8.8B
Other Current Liabilities	$1.4B
Other Non Current Liabilities	$412M
Total Shareholder Equity	-$70M
Treasury Stock	-
Retained Earnings	$443M
Common Stock	$3M
Common Stock Shares Outstanding	$256M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	$2B
Payments For Operating Activities	$156M
Proceeds From Operating Activities	-
Change In Operating Liabilities	$281M
Change In Operating Assets	$452M
Depreciation Depletion And Amortization	$236M
Capital Expenditures	$253M
Change In Receivables	$212M
Change In Inventory	$230M
Profit Loss	$1B
Cashflow From Investment	-$260M
Cashflow From Financing	-$569M
Proceeds From Repayments Of Short Term Debt	$0
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	$294M
Dividend Payout Common Stock	$294M
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	$80M
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$17M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$1B

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$1.7B
Total Revenue	$6.3B
Cost Of Revenue	$4.6B
Costof Goods And Services Sold	$2.5B
Operating Income	-$922M
Selling General And Administrative	$1.9B
Research And Development	$528M
Operating Expenses	$2.6B
Investment Income Net	-
Net Interest Income	-$527M
Interest Income	-
Interest Expense	$527M
Non Interest Income	-$42M
Other Non Operating Income	-
Depreciation	$120M
Depreciation And Amortization	$116M
Income Before Tax	$673M
Income Tax Expense	-$350M
Interest And Debt Expense	$527M
Net Income From Continuing Operations	$1B
Comprehensive Income Net Of Tax	$1B
Ebit	$1.2B
Ebitda	$1.3B
Net Income	$1B

Dividends

Field	Value
Ex Dividend Date	2025-02-24
Declaration Date	2025-02-13
Record Date	2025-02-24
Payment Date	2025-03-13
Amount	0.28

OGN Profile

Organon & Co Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.76	0.18%	$220.07B	7,844,359

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669